BACKGROUND: The relationship between cardiovascular factors and death can vary with age, very few studies have examined metabolic syndrome in the elderly. OBJECTIVE: The aim of this study is to assess the prevalence of the MS in a sample of elderly institutionalized patients (> 65 years) using ATPIII and IDF definitions. DESIGN: This was a cross-sectional survey covering a sample of representative of the institutionalized Spanish population aged above 65 years. The final sample study consisted of 862 patients, 556 females and 306 males. ATPIII and IDF definitions were used to classify the patients. RESULTS: Prevalence of MS was different according to the two definitions used. When the IDF definition was applied, total prevalence was 48.91% (CI 95%:43.47-50.25), while prevalence according to ATPIII criteria was 46.80% (CI = 43.47-50.25). a higher prevalence of MS was found in females as compared to males. Using IDF criteria, odds ratio was 1.9 (CI 95%:1.4-2.6) and 1.7 (CI 95%:1.2-2.2) according to ATPIII criteria. a steady decrease is seen in MS prevalence as the age of patients increases (the last two groups (85-94 ys and > 95 ys), both for the ATP III and the IDF definitions. CONCLUSION: A higher prevalence of MS in this elderly population as compared to general population was observed. A decrease of this prevalence above 95 years was detected.
BACKGROUND: The relationship between cardiovascular factors and death can vary with age, very few studies have examined metabolic syndrome in the elderly. OBJECTIVE: The aim of this study is to assess the prevalence of the MS in a sample of elderly institutionalized patients (> 65 years) using ATPIII and IDF definitions. DESIGN: This was a cross-sectional survey covering a sample of representative of the institutionalized Spanish population aged above 65 years. The final sample study consisted of 862 patients, 556 females and 306 males. ATPIII and IDF definitions were used to classify the patients. RESULTS: Prevalence of MS was different according to the two definitions used. When the IDF definition was applied, total prevalence was 48.91% (CI 95%:43.47-50.25), while prevalence according to ATPIII criteria was 46.80% (CI = 43.47-50.25). a higher prevalence of MS was found in females as compared to males. Using IDF criteria, odds ratio was 1.9 (CI 95%:1.4-2.6) and 1.7 (CI 95%:1.2-2.2) according to ATPIII criteria. a steady decrease is seen in MS prevalence as the age of patients increases (the last two groups (85-94 ys and > 95 ys), both for the ATP III and the IDF definitions. CONCLUSION: A higher prevalence of MS in this elderly population as compared to general population was observed. A decrease of this prevalence above 95 years was detected.
Authors: Ann Marie McNeill; Wayne D Rosamond; Cynthia J Girman; Sherita Hill Golden; Maria I Schmidt; Honey E East; Christie M Ballantyne; Gerardo Heiss Journal: Diabetes Care Date: 2005-02 Impact factor: 19.112
Authors: David W Dunstan; Paul Z Zimmet; Timothy A Welborn; Maximilian P De Courten; Adrian J Cameron; Richard A Sicree; Terry Dwyer; Stephen Colagiuri; Damien Jolley; Matthew Knuiman; Robert Atkins; Jonathan E Shaw Journal: Diabetes Care Date: 2002-05 Impact factor: 19.112
Authors: David E Laaksonen; Hanna-Maaria Lakka; Leo K Niskanen; George A Kaplan; Jukka T Salonen; Timo A Lakka Journal: Am J Epidemiol Date: 2002-12-01 Impact factor: 4.897
Authors: Daniel Antonio de Luis; Rocio Aller; Olatz Izaola; Manuel Gonzalez Sagrado; Rosa Conde; David Primo; Beatriz de la Fuente; Hilda F Ovalle; Marta Ruiz Mambrilla Journal: J Clin Lab Anal Date: 2012-07 Impact factor: 2.352
Authors: Mohammadhosain Afrand; Saeed Hossein Khalilzadeh; Ahmad Shojaoddiny-Ardekani; Mohammad Afkhami-Ardekani; Azita Ariaeinejad Journal: Med J Islam Repub Iran Date: 2016-05-16
Authors: Katharina Wittmann; Cornel Sieber; Simon von Stengel; Matthias Kohl; Ellen Freiberger; Franz Jakob; Michael Lell; Klaus Engelke; Wolfgang Kemmler Journal: Clin Interv Aging Date: 2016-11-18 Impact factor: 4.458
Authors: Subhashish Agarwal; Janet A Tooze; Douglas C Bauer; Jane A Cauley; Tamara B Harris; Annemarie Koster; Catherine R Womack; Stephen B Kritchevsky; Denise K Houston Journal: Int J Endocrinol Date: 2021-03-13 Impact factor: 3.257